세계의 림프부종 치료 시장(2023-2030년) : 최종사용자, 제품 유형, 증상 유형, 치료 유형별 규모, 점유율, 성장 분석, 예측
Global Lymphedema Treatment Market Size, Share, Growth Analysis, By End-User, By Product, By Condition Type, By Treatment Type - Industry Forecast 2023-2030
림프부종 치료 시장 규모는 2021년에 7억 8,653만 달러, 2022년에 8억 6,014만 달러를 나타내고, 2023년에서 2030년까지 예측기간 중 9.5%의 CAGR로 성장하여 2030년에는 17억 3,536만 달러 규모로 성장할 것으로 예측됩니다.
유방암 발생률 상승, 림프부종 유병률 상승, 시장 진출 기업에 의한 다수의 신제품 도입, 기술 진보 결과로서 효율적인 제품에 대한 요구 상승 등이 림프부종 치료 시장 성장을 촉진하는 주요 요인이 되고 있습니다.
세계의 림프부종 치료 시장을 조사했으며, 시장 개요, 시장에 대한 각종 영향요인 분석, 기술·혁신 동향, 시장 규모 추정과 예측, 각종 부문·지역별 내역, 경쟁 상황, 주요 기업 개요 등을 정리했습니다.
Lymphedema Treatment Market size was valued at USD 786.53 million in 2021 and is poised to grow from USD 860.14 million in 2022 to USD 1735.36 million by 2030, growing at a CAGR of 9.5% in the forecast period (2023-2030).
A condition known as lymphedema is characterised by abnormal swelling of the body brought on by lymphocytosis as a result of lymphatic system failure. The lower extremity is affected 90% of the time, the upper extremity 10%, and the genitalia 1%. The most common cause of lymphedema (filariasis) is an infection brought on by the parasite Wuchereria bancrofti. Lymphedema is among the most dreaded and unlucky side effects of breast cancer treatment. According to a National Centre for Biotechnology Information (NCBI) research, 40 percent of breast cancer patients experienced lymphedema. The primary factors driving the growth of the lymphedema treatment market are the rising incidence of breast cancer, the rising prevalence of lymphedema, the introduction of several new products by prominent market participants, and the rising need for efficient products as a consequence of technological advancements.
The lymph node draining condition known as lymphedema can appear in cancer patients before or after treatment, according to the US Department of Health and Human Services. For instance, it has been noted that it may occur immediately or up to 30 years after breast cancer treatment. Additionally, 80% of patients start showing symptoms 3 years after surgery, with the remaining 20% developing edoema at a rate of 1% every year. Additionally, after the treatment of gynecologic cancer, a sizeable patient population, primarily women, develops lower-limb lymphedema, with vulvar cancer survivors having the highest frequency (37%) and ovarian cancer survivors having the lowest prevalence (7%). Additionally, the incidence of arm lymphedema varied from 8% to 56% two years after surgery. According to the Alliance Z 1071 longitudinal substudy of the American College of Surgeons Oncology Group (ACOSOG), participants in breast cancer trials report a 3-year cumulative incidence of arm edoema and arm heaviness. Cutting edge and very effective cancer treatment options aid in lowering the risk of lymphedema. The major players in the market for cancer therapeutics are working very hard to introduce innovative products as a result.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lymphedema Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Segments covered in this report:
Based on end-user, the market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others. Based on product, the market is segmented into compression bandages, compression stockings, pneumatic compression devices, others. Based on affected area, the market is segmented into Genital, Lower Extremity, Upper Extremity and Others. Based on age group, the market is segmented into adult and geriatric. Based on route of administration, the market is segmented into Oral, Injectable and Others. Based on type, the market is segmented into primary and secondary lymphedema. Based on condition type, the market is segmented into cancer, cardiovascular diseases, inflammatory diseases, and others. Based on treatment type, the market is segmented into Compression Therapy, Surgery, Drug Therapy, Laser Therapy, and Others. Based on region, the global market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.
As cases of breast cancer and lymphedema rise, it is projected that the market for lymphedema treatments would expand. The likelihood of developing cancer is predicted to rise, creating tremendous opportunity for market expansion. Increasing health spending and growing investments in drug discovery research and development have increased the demand for healthcare facilities. The development of novel lymphedema treatment options is also projected to support market expansion throughout the forecasted period.
The market expansion in the upcoming years is projected to be accelerated by technological developments in lymphedema treatment methods. Additionally, the rise of the market is undoubtedly facilitated by the government's favourable programmes and the reimbursement requirements.
Despite advances in technology, there is still no permanent treatment for lymphedema, which is anticipated to limit market growth.
The high cost of procedures and treatments is anticipated to restrict market growth.
As more people experience the ailment, the market for lymphedema treatments is anticipated to grow. Additionally, innovative and cutting-edge treatments are being developed at an exponential rate to lower risk throughout treatment as the disease develops further. Increasing healthcare spending is also predicted to spur industry growth and an increase in healthcare innovation. Additionally, pharmaceutical companies are encouraging worldwide business globalisation by introducing cutting-edge medical equipment.